Coronary Artery Disease (CAD) is a leading cause of morbidity and mortality worldwide. CAD is one of the prevalent disease of South East Asia, and about 12 million Pakistanis are suffering (or at the risk) of IHD (Ischemic heart disease).
Total ANTIANGINAL market in Pakistan is worth 1.01 billion PKR (IMS MAT Q3 2014) (Nitrates & Coronary therapy combined) C01D Coronary therapy market is growing by 22%.
Ikodil (Nicorandil) has a hybrid vasodilatory effect, which is produced by activating ATP-dependant potassium channels as well as its nitrate component causes dilation of systemic venous circulation and epicardial coronary arteries
Ikodil is promoted in indication of Chronic Angina Pectoris, Myocardial Infarction (STEMI, NSTEMI). It is recommended by ESC Guidelines 2013, for the treatment of ANGINA, MI and Ischemia. Ikodil is positioned as “The recommended, effective & long term treatment of Angina having hybrid mechanism of action, backed with OBS quality”.
Ikodil Internal Launch Training was held on 6th & 7th February, 2015 in Karachi. CV-1 team participated at a two-day aggressive training which covered the Medical aspects. This medical training was followed by the Marketing elements of Ikodil, Strategy to achieve targets, the Key selling messages, and Detailing competition.
Ikodil Field Launch was done aggressively by OBS Pakistan (Pvt.) Ltd. on 9th February with launch ceremonies in leading cardiology institutes of Pakistan, and the HCPs appreciated this launch with a very positive response through their prescriptions.
OBS Pakistan (Pvt.) Ltd. is very positive and has high hopes to make Ikodil as a drug of choice for HCPs in coronary therapy market. OBS Pakistan (Pvt.) Ltd. is very optimistic that with Ikodil we will be able to achieve the objective of “Making a Difference in People’s (Patients) lives”.